StockData
Monopar Therapeutics logo

Monopar Therapeutics (MNPR) stock

MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$71.06−0.91 (-1.26%)

Close on Nov 17, 2026Market cap $476.97MP/E –Yield –

Monopar Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Monopar Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $14.78M, up 3.5% year over year. For fiscal 2025 it was $9.90M, down 23.8% from the year before. The highest annual figure on record is $13.01M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.90M-23.8%
FY2024Dec 31, 2024$13.01M+132.2%
FY2023Dec 31, 2023$5.60M-26.2%
FY2022Dec 31, 2022$7.59M+16.9%
FY2021Dec 31, 2021$6.49M+59.7%
FY2020Dec 31, 2020$4.07M+106.5%
FY2019Dec 31, 2019$1.97M+10.9%
FY2018Dec 31, 2018$1.77M+89.7%
FY2017Dec 31, 2017$935.32K+233.6%
FY2016Dec 31, 2016$280.36K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$4.77M+175.5%
Q1 FY2026Mar 31, 2026$3.49M+112.2%
Q4 FY2025Dec 31, 2025$3.94M-60.3%
Q3 FY2025Sep 30, 2025$2.59M+163.1%
Q2 FY2025Jun 30, 2025$1.73M+53.0%
Q1 FY2025Mar 31, 2025$1.64M+70.1%
Q4 FY2024Dec 31, 2024$9.92M+858.4%
Q3 FY2024Sep 30, 2024$984.28K-25.2%
Q2 FY2024Jun 30, 2024$1.13M-29.1%
Q1 FY2024Mar 31, 2024$966.11K-41.6%
Q4 FY2023Dec 31, 2023$1.04M-50.8%
Q3 FY2023Sep 30, 2023$1.32M-24.0%
Q2 FY2023Jun 30, 2023$1.59M-23.3%
Q1 FY2023Mar 31, 2023$1.65M-1.5%
Q4 FY2022Dec 31, 2022$2.10M+6.1%
Q3 FY2022Sep 30, 2022$1.73M-5.2%
Q2 FY2022Jun 30, 2022$2.08M+40.8%
Q1 FY2022Mar 31, 2022$1.68M+39.0%
Q4 FY2021Dec 31, 2021$1.98M+21.5%
Q3 FY2021Sep 30, 2021$1.83M+45.5%
Q2 FY2021Jun 30, 2021$1.48M+77.3%
Q1 FY2021Mar 31, 2021$1.21M+250.4%
Q4 FY2020Dec 31, 2020$1.63M+179.6%
Q3 FY2020Sep 30, 2020$1.26M+471.3%
Q2 FY2020Jun 30, 2020$832.50K+152.8%
Q1 FY2020Mar 31, 2020$344.41K-58.8%
Q4 FY2019Dec 31, 2019$583.78K+12.1%
Q3 FY2019Sep 30, 2019$219.85K-27.6%
Q2 FY2019Jun 30, 2019$329.29K+8.4%
Q1 FY2019Mar 31, 2019$835.60K+82.8%
Q4 FY2018Dec 31, 2018$520.98K+68.4%
Q3 FY2018Sep 30, 2018$303.68K+68.1%
Q2 FY2018Jun 30, 2018$303.68K-2.5%
Q1 FY2018Mar 31, 2018$457.14K+241.8%
Q4 FY2017Dec 31, 2017$309.32K–
Q3 FY2017Sep 30, 2017$180.68K–
Q2 FY2017Jun 30, 2017$311.59K–
Q1 FY2017Mar 31, 2017$133.74K–

More Monopar Therapeutics figures

See a number that looks wrong?